Protagenic Therapeutics (PTIX) chair buys more stock
Rhea-AI Filing Summary
Protagenic Therapeutics, Inc. (PTIX) reported that director and executive chair Armen Garo H purchased 2,700 shares of common stock on 2026-08-19 in an open-market or private transaction at $0.35 per share. Following this purchase, he directly owns 36,899 common shares. The transaction was not indicated as pursuant to a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,700 shares
Net Buy
1 txn
Insider
ARMEN GARO H
Role
EXEC. CHAIR & PRINCIPAL OFF
Bought
2,700 shs ($945.00)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 2,700 | $0.35 | $945.00 |
Holdings After Transaction:
COMMON STOCK — 36,899 shares (Direct)
Key Figures
Shares purchased: 2,700 shares
Purchase price: $0.35 per share
Shares owned after transaction: 36,899 shares
3 metrics
Shares purchased
2,700 shares
Common stock purchased on 2026-08-19 by Armen Garo H
Purchase price
$0.35 per share
Price for common stock purchase on 2026-08-19
Shares owned after transaction
36,899 shares
Direct common stock ownership by Armen Garo H after the purchase
Key Terms
Form 4, open market or private transaction, Rule 10b5-1 trading plan
3 terms
Form 4 regulatory
"Protagenic Therapeutics (PTIX) insider transaction was reported on a Form 4"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
open market or private transaction financial
"Transaction code description is Purchase in open market or private transaction"
Rule 10b5-1 trading plan regulatory
"The transaction was not indicated as pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
What insider transaction did PTIX report for Armen Garo H?
Protagenic Therapeutics (PTIX) reported that Armen Garo H bought 2,700 common shares on 2026-08-19. The shares were acquired in a purchase in open market or private transaction at $0.35 per share, increasing his direct holdings.
Was the recent PTIX insider trade under a Rule 10b5-1 trading plan?
The filing indicates the transaction was not affirmed as under a Rule 10b5-1 trading plan. The document-level checkbox for Rule 10b5-1 was marked false, and no footnotes describe this purchase as pursuant to a trading plan.
What role does Armen Garo H hold at Protagenic Therapeutics (PTIX)?
Armen Garo H is reported as a director and officer of Protagenic Therapeutics, with the title EXEC. CHAIR & PRINCIPAL OFF. His recent Form 4 discloses a purchase of 2,700 common shares, bringing direct ownership to 36,899 shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
